From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

loncastuximab tesirine   Click here for help

GtoPdb Ligand ID: 11521

Synonyms: ADCT-402 | ADCT402 | loncastuximab tesirine-lpyl | RB4v1.2-SG-3249 | Zynlonta®
Approved drug
loncastuximab tesirine is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate that delivers the toxic payload teserine (pyrrolobenzodiazepine dimer SG3249, which acts as a DNA alkylating and cross-linking agent [3]) to CD19-expressing B cells [4].
No information available.
Summary of Clinical Use Click here for help
Loncastuximab tesirine was advenced to clinical evaluation for B cell malignancies [1-2]. IT was approved by the FDA in April 2021 (via the accelerated approval route), as a therapy for previously treated relapsed or refractory large B-cell lymphoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02669017 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Phase 1 Interventional ADC Therapeutics S.A. 1